Metabolic HealthSemaglutide Trials Barely Looked at Oral Health Despite Years of Safety Data
Semaglutide, the GLP-1 drug used for type 2 diabetes and weight loss, is well known for causing nausea and diarrhea. This scoping review searched three databases for randomized trials from 2019 to 2025 and found 12 that met its criteria. Nausea appeared in all 12 trials and diarrhea in 11. Pancreatitis, liver and gallbladder problems were reported in a few trials, with low event counts. Oral side effects were barely documented: dry mouth appeared in one trial and dental caries in another, and none of the trials was designed to study the mouth or teeth. The authors conclude that the drug's safety profile looks favorable overall, but that the evidence on oral health is too thin to draw conclusions. They call for future trials to include standardized dental assessments and longer follow-up.